Search

Author/Creator Derfuss, T.

1. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. (19th January 2018)

Authors:
Montalban, X.; Gold, R.; Thompson, A. J.; Otero‐Romero, S.; Amato, M. P.; Chandraratna, D.; Clanet, M.; Comi, G.; Derfuss, T.; Fazekas, F.; Hartung, H. P.; Havrdova, E.; Hemmer, B.; Kappos, L.; Liblau, R.; Lubetzki, C.; Marcus, E.; Miller, D. H.; Olsson, T.; Pilling, S.
Journal:
European journal of neurology
Issue:
Volume 25:Number 2(2018)
Page Start:
215
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment. (3rd April 2020)

Authors:
von Wyl, V.; Décard, B. F.; Benkert, P.; Lorscheider, J.; Hänni, P.; Lienert, C.; Kuhle, J.; Derfuss, T.; Kappos, L.; Yaldizli, Ö.
Journal:
European journal of neurology
Issue:
Volume 27:Number 6(2020)
Page Start:
1066
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Issue 4 (April 2020)

Authors:
Derfuss, T.; Weber, M.; Hughes, R.; Eggebrecht, J.; Wang, Q.; Sauter, A.; Koendgen, H.; Hauser, S.; Bar-Or, A.; Hartung, H.P.
Journal:
Clinical neurophysiology
Issue:
Volume 131:Issue 4(2020:Apr.)
Page Start:
e196
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗